IX Biopharma's (SGX:42C) net loss narrowed to SG$6.3 million for the half year ended Dec. 31, 2024, from SG$7.3 million a year earlier, a filing with the Singapore Exchange said on Friday.
Basic loss per share came in at SG$0.0072 from SG$0.0096 in the comparable period.
Revenue jumped 39% year over year to SG$3.7 million from SG$2.7 million, driven by stronger sales of medicinal cannabis products and services in Australia.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。